Japan Society of Gynecologic Oncology guidelines 2013 for the treatment of uterine body neoplasms.
The third version of the Japan Society of Gynecologic Oncology guidelines for the treatment of uterine body neoplasms was published in 2013. The guidelines comprise nine chapters and nine algorithms. Each chapter includes a clinical question, recommendations, background, objectives, explanations, and references. This revision was intended to collect up-to-date international evidence. The highlights of this revision are to (1) newly specify costs and conflicts of interest; (2) describe the clinical significance of pelvic lymph node dissection and para-aortic lymphadenectomy, including variant histologic types; (3) describe more clearly the indications for laparoscopic surgery as the standard treatment; (4) provide guidelines for post-treatment hormone replacement therapy; (5) clearly differentiate treatment of advanced or recurrent cancer between the initial treatment and the treatment carried out after the primary operation; (6) collectively describe fertility-sparing therapy for both atypical endometrial hyperplasia and endometrioid adenocarcinoma (corresponding to G1) and newly describe relapse therapy after fertility-preserving treatment; and (7) newly describe the treatment of trophoblastic disease. Overall, the objective of these guidelines is to clearly delineate the standard of care for uterine body neoplasms in Japan with the goal of ensuring a high standard of care for all Japanese women diagnosed with uterine body neoplasms.
Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan. ebiyas@med.kobe-u.ac.jp.
Yasuhiko
Y
Ebina
Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Hidetaka
H
Katabuchi
Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Japan.
Mikio
M
Mikami
Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata, Japan.
Satoru
S
Nagase
Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Nobuo
N
Yaegashi
Fujita Health University School of Medicine, Toyoake, Japan.
Yasuhiro
Y
Udagawa
Division of Gynecologic Oncology, National Hospital Organization, Hokkaido Cancer Center, Sapporo, Japan.
Hidenori
H
Kato
Department of Obstetrics and Gynecology, Toho University School of Medicine, Toho University Medical Center Ohashi Hospital, Tokyo, Japan.
Kaneyuki
K
Kubushiro
Department of Obstetrics and Gynecology, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Chiba, Japan.
Kiyoshi
K
Takamatsu
Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan.
Kazuhiko
K
Ino
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Hiroyuki
H
Yoshikawa
D000465:Algorithms; D001011:Aorta; D005260:Female; D059247:Fertility Preservation; D020249:Hormone Replacement Therapy; D006801:Humans; D007044:Hysterectomy; D007564:Japan; D010535:Laparoscopy; D008197:Lymph Node Excision; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D010388:Pelvis; D014328:Trophoblastic Neoplasms / Q000628:therapy*; D014594:Uterine Neoplasms / Q000628:therapy*
Clinical practice guidelines; Endometrial cancer; Treatment; Trophoblastic disease; Uterine sarcoma